A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT05414175
- Phase
- PHASE3
- Status
- Completed
Conditions
- Cardiomyopathy, Hypertrophic Obstructive
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Mavacamten — DRUGSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the effectiveness, safety, and tolerability of a 30-week course of mavacamten and the long-term effects of mavacamten in Japanese participants with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Key Dates
- Start date
- Aug 19, 2022
- Status verified
- Jan 2026
- Primary completion
- Nov 27, 2023
- Completion
- Dec 11, 2025
Study Design
- Enrollment
- 38 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Mavacamten
Primary Outcome Measure
Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 [ Time Frame: At Baseline and Week 30 ]